

TITLE OF INVENTION: FUSION POLYPEPTIDE AJ007 AND USE THEREOF

ABSTRACT

This application discloses a fusion polypeptide AJ007 and use thereof, and belongs to the technical field of ophthalmic drugs. The fusion polypeptide AJ007 is formed by linking a TAT cell-penetrating peptide to a front end of a polypeptide HM-1 molecule that inhibits neovascularization. The fusion polypeptide AJ007 is used for preparing polypeptide eye drops. By selecting a prescription of this application, the fusion polypeptide AJ007 is prepared into eye drops. When a wet age-related macular degeneration disease is prevented or treated, an administration route of the eye drops can effectively avoid the problems of various serious side effects and poor patient tolerance caused by intravitreal injection clinically, has the advantage of non-invasive treatment, and exhibits excellent efficacy of improving abnormal proliferation of choroidal neovascularization in the laser-induced wAMD mouse model, thereby having good clinical treatment potential.

FIG. 10